Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Generex Biotechnology Corp GNBT
(Total Views: 537)
Posted On: 08/26/2020 3:25:50 PM
Post# of 36566
Posted By: skipper1072
New BARDA Awards:


Esperovax, Inc. USA
Product Name: Egress RD mRNA Oral Cellular Vaccine Delivery Technology

Description:
An oral immunization for COVID-19 involving delivery of enveloped virus like particles (eVLPs) by capsule to the gut that will induce immune protection against disease.

Unique Impact:
This technology aims to provide a cost-effective technological innovation that improves immunization uptake, coverage, compliance and preparedness, with the potential for self-administration

Base Award Amount: $606,780.00 (July 27, 2020)
Cost Share: Yes

University of Connecticut USA
Product Name: Single-Administration Microneedle Skin Patch for Pandemic Vaccine

Description:
An easy-to-use vaccine-delivery microneedle (MN) patch (i.e., Micro Array Patch) that will contain the spike protein (the S-protein on the shell of COVID-19 virus) and be programmed to automatically deliver this S-protein (as an antigen against COVID-19) into the skin.

Unique Impact:
This technology has the potential for mass distribution of self-administered immunizations that rival or potentially surpass the effectiveness of an immunization delivered via traditional needle and syringe.

Base Award Amount: $432,990.00 (August 17, 2020)
Cost Share: Yes

Vaxess Technologies, Inc. USA
Product Name: MIMIX-COVID Pre-fusion Spike Protein Micro Array Patch

Description:
MIMIX Vaccine Patch Development and Scaling of shelf-stable, self-applied, single-dose Micro Array Patch (MAP) technology

Unique Impact:
This technology could open the profound potential for large-scale distribution of self-administered immunizations that rival or potentially surpass the effectiveness of an immunization delivered via traditional needle and syringe.

Base Award Amount: $749,000.00 (August 9, 2020)
Cost Share: Yes

Verndari, Inc. USA
Product Name: VaxiPatchâ„¢ Complete Vaccination Kit

Description:
SARS-CoV-2 Recombinant Spike Receptor Binding Domain protein administered via Micro Array Patch (MAP) Technology

Unique Impact:
This technology aims to provide a cost-effective technological innovation that improves immunization uptake, coverage, compliance and preparedness, with the potential for self-administration.

Base Award Amount: $698,215.00 (July 23, 2020)
Cost Share: Yes













(0)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site